recent articles
Proscia and Visiopharm: Partnership to improve clinical decision making for breast and colon cancer care HOERSHOLM, Denmark & PHILADELPHIA – March 22, 2022 – Proscia®, a leader in digital and computational pathology solutions, and...
Aiforia announces the CE-IVD mark of its Aiforia® Clinical AI Model for Lung Cancer; PD-L1 for assisting pathologists in the fast and accurate primary diagnosis of lung cancer. This latest AI model expands Aiforia’s portfolio of clinical...
The CE-IVD marked AI model for Ki67 is the first model to be released as part of the Aiforia Clinical Suite for Breast Cancer, supporting pathologists in cancer diagnosis. First-of-its kind diagnostic tool Aiforia today announced the CE-IVD...
Aiforia Introduces Velocity, the Latest Software Release of High-Sp...
- Anatomic Pathology
- Artificial Intelligence
- Clinical Laboratories
- Cloud Computing
- Data Management
- Device Manufacturers
- Digital Pathology News
- File format
- Health Technology Collaboration
- Image Analysis
- Informatics
- International
- Laboratory Informatics
- Laboratory Management & Operations
- Medical Research
- New Digital Imaging Technologies
- Pathology News
- Vendor products
- Web/Tech
- Whole slide
Aiforia announced the release of Velocity, the latest software release of tools, features and a new product, built upon the current scalable cloud platform, that allow medical and scientific experts to speed-up and simplify image analysis,...
Promega Corporation intends to seek FDA approval and CE-IVD marking for a commercially available Microsatellite Instability (MSI) assay to assist oncologists and pathologists in determining colorectal cancer decisions. The current Promega...
HalioDx receives CLIA Compliance for its laboratory based in Marseille Immunoscore® Colon, is now available to US patients in selected states with a turnaround time of 10 days Marseille, June 21, 2017 - HalioDx announced today that...
